PRNewsWire
14 Aug 2026, 02:44 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Cellebrite DI (CLBT) reduced its 2026 ARR guidance to $550 million–$560 million (14%-16% growth) from a previous projection of $567 million–$573 million (18%-19% growth). — A downward revision in growth guidance and revenue targets directly signals weakening fundamentals and usually leads to valuation deratings.
-0.70Law firm Levi & Korsinsky is investigating Cellebrite DI for potential securities fraud regarding misleading disclosures about its 2026 outlook. — Legal investigations into financial disclosures create overhang and risk of costly class-action settlements.
-0.40Cellebrite's net new ARR performance shifted from being 'back to prior year levels' in Q4 2025 to being 'roughly flat year-over-year' by Q2 2026. — Stagnation in net new ARR indicates a slowdown in customer acquisition or expansion, undermining the growth narrative.
-0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a shareholder investigation following a 30% stock price drop, missed revenue targets, and lowered guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
